Could Camrelizumab Plus Chemotherapy Improve Clinical Outcomes in Advanced Malignancy? A Systematic Review and Network Meta-Analysis

PURPOSE: Camrelizumab is a novel programmed cell death 1 (PD-1) inhibitor. To determine the efficacy and safety of the combination treatment of camrelizumab+chemotherapy and camrelizumab monotherapy, and determine which is the most suitable malignancy type to be treated with camrelizumab, we perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chao, Xu, Chang, Li, Xiang, Zhang, Yaowen, Zhang, Simeng, Zhang, Tongyu, Zhang, Yingshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415159/
https://www.ncbi.nlm.nih.gov/pubmed/34485135
http://dx.doi.org/10.3389/fonc.2021.700165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415159/
https://www.ncbi.nlm.nih.gov/pubmed/34485135
http://dx.doi.org/10.3389/fonc.2021.700165

Ejemplares similares